Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used

Autores
Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; Marin, Gustavo Horacio
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks.
Fil: Marin, Lupe. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina
Fil: Blanco, Luis. No especifíca;
Fil: Marin, Gina. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina
Fil: Aguero, Sergio. No especifíca;
Fil: Pagnotta, Mariana. No especifíca;
Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
Materia
CONTRACEPTIVES
THROMBOSIS
PROGESTIN
RISK
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/139291
Acceder
id CONICETDig_c7092df4ba58b0bcce2ab850a9e3aee7
oai_identifier_str oai:ri.conicet.gov.ar:11336/139291
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination usedMarin, LupeBlanco, LuisMarin, GinaAguero, SergioPagnotta, MarianaMarin, Gustavo HoracioCONTRACEPTIVESTHROMBOSISPROGESTINRISKhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks.Fil: Marin, Lupe. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; ArgentinaFil: Blanco, Luis. No especifíca;Fil: Marin, Gina. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; ArgentinaFil: Aguero, Sergio. No especifíca;Fil: Pagnotta, Mariana. No especifíca;Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaSociety of Pharmaceutical Technocrats2020-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/139291Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; et al.; Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used; Society of Pharmaceutical Technocrats; Journal of Drug Delivery and Therapeutics; 10; 5; 9-2020; 198-2012250-1177CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.22270/jddt.v10i5.4315info:eu-repo/semantics/altIdentifier/url/http://jddtonline.info/index.php/jddt/article/view/4315info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:58:03Zoai:ri.conicet.gov.ar:11336/139291instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:58:03.253CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
title Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
spellingShingle Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
Marin, Lupe
CONTRACEPTIVES
THROMBOSIS
PROGESTIN
RISK
title_short Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
title_full Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
title_fullStr Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
title_full_unstemmed Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
title_sort Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used
dc.creator.none.fl_str_mv Marin, Lupe
Blanco, Luis
Marin, Gina
Aguero, Sergio
Pagnotta, Mariana
Marin, Gustavo Horacio
author Marin, Lupe
author_facet Marin, Lupe
Blanco, Luis
Marin, Gina
Aguero, Sergio
Pagnotta, Mariana
Marin, Gustavo Horacio
author_role author
author2 Blanco, Luis
Marin, Gina
Aguero, Sergio
Pagnotta, Mariana
Marin, Gustavo Horacio
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv CONTRACEPTIVES
THROMBOSIS
PROGESTIN
RISK
topic CONTRACEPTIVES
THROMBOSIS
PROGESTIN
RISK
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks.
Fil: Marin, Lupe. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina
Fil: Blanco, Luis. No especifíca;
Fil: Marin, Gina. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata; Argentina
Fil: Aguero, Sergio. No especifíca;
Fil: Pagnotta, Mariana. No especifíca;
Fil: Marin, Gustavo Horacio. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
description Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin.Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic eventsassociated to oral contraceptive use, we developed the present study.Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex,combination consumed, doses, co-morbidities, thrombotic events.Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel,gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (eitherdepth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generationoptions). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins whencompared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestindenote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies thatprovide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning.However, the combinations provided should not expose population to additional and unnecessary risks.
publishDate 2020
dc.date.none.fl_str_mv 2020-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/139291
Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; et al.; Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used; Society of Pharmaceutical Technocrats; Journal of Drug Delivery and Therapeutics; 10; 5; 9-2020; 198-201
2250-1177
CONICET Digital
CONICET
url http://hdl.handle.net/11336/139291
identifier_str_mv Marin, Lupe; Blanco, Luis; Marin, Gina; Aguero, Sergio; Pagnotta, Mariana; et al.; Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used; Society of Pharmaceutical Technocrats; Journal of Drug Delivery and Therapeutics; 10; 5; 9-2020; 198-201
2250-1177
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.22270/jddt.v10i5.4315
info:eu-repo/semantics/altIdentifier/url/http://jddtonline.info/index.php/jddt/article/view/4315
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Society of Pharmaceutical Technocrats
publisher.none.fl_str_mv Society of Pharmaceutical Technocrats
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782293668003840
score 12.982451

Publicaciones similares